论文部分内容阅读
目的:观察盐酸米多君治疗血液透析(HD)中低血压的疗效。方法:60例HD中出现低血压的患者随机分为治疗组与对照组各30例。治疗组于HD开始前15 min服用盐酸米多君5 mg。透析开始后2h再加服5mg。对照组予以HD中禁食、高低钠序贯透析,输注高渗葡萄糖及0.9%氯化钠注射液、低温HD等治疗措施。于HD前与结束后各测1次血压,HD开始后每30 min测量1次,共10次。观察比较患者用药前后血压的变化。结果:用药后患者的血压较治疗前明显升高(P<0.01),其升高的幅度明显高于对照组(P<0.01),总有效率达到83.3%,亦明显高于对照组(P<0.05),无不良反应发生。结论:盐酸米多君治疗HD中低血压安全有效。
Objective: To observe the efficacy of midodrine hydrochloride in the treatment of hypotension in hemodialysis (HD). Methods: Sixty HD patients with hypotension were randomly divided into treatment group and control group of 30 cases. The treatment group was given 5 mg of midodrine hydrochloride 15 min before the start of HD. 2h after dialysis plus 5mg. The control group was fasted in HD, high and low sodium sequential dialysis, infusion of hypertonic glucose and 0.9% sodium chloride injection, low-temperature HD and other therapeutic measures. Blood pressure was measured before and after HD. Blood pressure was measured every 30 minutes after HD started, a total of 10 times. Observation and comparison of patients before and after treatment of blood pressure changes. Results: After treatment, the blood pressure of patients was significantly higher than that before treatment (P <0.01), and the increase was significantly higher than that of the control group (P <0.01). The total effective rate was 83.3%, which was also significantly higher than that of the control group <0.05), no adverse reactions occurred. Conclusion: Midodrine hydrochloride is safe and effective in treating hypotension in HD.